Oric Pharmaceuticals, Inc. financial data

Symbol
ORIC on Nasdaq
Location
240 E. Grand Ave., 2 Nd Floor, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.31K % -9.54%
Debt-to-equity 8.48 % -8.42%
Return On Equity -45.3 % -6.74%
Return On Assets -41.8 % -7.51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97.4M shares +38%
Common Stock, Shares, Outstanding 97.3M shares +37.9%
Entity Public Float 471M USD +13.6%
Common Stock, Value, Issued 11K USD +57.1%
Weighted Average Number of Shares Outstanding, Basic 99M shares +40.3%
Weighted Average Number of Shares Outstanding, Diluted 99M shares +40.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 32.1M USD +13.9%
Operating Income (Loss) -148M USD -9.85%
Nonoperating Income (Expense) 12.8M USD -14.3%
Net Income (Loss) Attributable to Parent -135M USD -12.8%
Earnings Per Share, Basic -1 USD/shares +3.33%
Earnings Per Share, Diluted -1 USD/shares +3.33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.7M USD +12.3%
Assets, Current 296M USD +5.79%
Property, Plant and Equipment, Net 2.56M USD -17.2%
Operating Lease, Right-of-Use Asset 8.38M USD -8.36%
Other Assets, Noncurrent 7.13M USD -25.4%
Assets 431M USD +42.7%
Accounts Payable, Current 2.9M USD -31.7%
Accrued Liabilities, Current 17.3M USD +1.65%
Liabilities, Current 20.2M USD -5.03%
Operating Lease, Liability, Noncurrent 6.17M USD -17.3%
Other Liabilities, Noncurrent 4.09M USD -40%
Liabilities 24.3M USD -13.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 615K USD -14.8%
Retained Earnings (Accumulated Deficit) -662M USD -25.7%
Stockholders' Equity Attributable to Parent 407M USD +48.5%
Liabilities and Equity 431M USD +42.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.5M USD -7.78%
Net Cash Provided by (Used in) Financing Activities 125M USD
Net Cash Provided by (Used in) Investing Activities 22.5M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 97.3M shares +37.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.1M USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.2M USD +12.2%
Deferred Tax Assets, Valuation Allowance 173M USD +29.8%
Deferred Tax Assets, Gross 175M USD +29.1%
Operating Lease, Liability 9.36M USD -8.38%
Depreciation 302K USD +15.7%
Payments to Acquire Property, Plant, and Equipment 387K USD +77.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -135M USD -14%
Lessee, Operating Lease, Liability, to be Paid 10.6M USD -12%
Property, Plant and Equipment, Gross 10.7M USD +4.06%
Operating Lease, Liability, Current 3.3M USD +5.77%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.46M USD +29.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.3M USD +15.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.22M USD -32.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.77M USD +3.51%
Deferred Tax Assets, Operating Loss Carryforwards 90.7M USD +19.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 3.74M USD +32.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.05M USD -62.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.59M USD -3.43%
Share-based Payment Arrangement, Expense 24M USD +26.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%